New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
168.85
2.32
+1.39%
Follow GILD
Alert me
Gilead Sciences, Inc. 8-K filed Feb 6, 2024
2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.